Yao Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yao Wang has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Gregory Edward Rice
Inoviq Ltd, Notting Hill, Australia
1 shared publication - Hiroshi Itoh
Tokyo University of Agriculture and Technology
1 shared publication Kai Zhang
Tianjin Key Laboratory of Medical Epigenetics, 2011 Collaborative Innovation Center of Tianjin for Medical, Epigenetics, Department of Biochemistry and Molecular Biology, Tianjin Medical University, Tianjin, China
1 shared publicationKaren Oliva
Gynaecological Cancer Research Centre, Royal Women’s Hospital, University of Melbourne, Melbourne, Australia
1 shared publication- Kentaro Kawasaki
Division of Gastroenterological Surgery, Department of Clinical Molecular Medicine
1 shared publication Koichi Narita
First Department of Surgery, Kobe, Japan
1 shared publication
Latest Publications
- 1 September 2019
- Published by Elsevier in Life Sciences
- Vol. 232, 116602
High glucose regulates ERp29 in hepatocellular carcinoma by LncRNA MEG3-miRNA 483-3p pathway
- 1 September 2019
- Published by Elsevier in Life Sciences
- Vol. 232, 116602
High glucose regulates ERp29 in hepatocellular carcinoma by LncRNA MEG3-miRNA 483-3p pathway
- 5 March 2003
- Published by Wiley in Proteomics
- Vol. 3 (3) , 288-298
Proteomic profiling of proteins associated with urokinase plasminogen activator receptor in a colon cancer cell line using an antisense approach
Expression of urokinase plasminogen activator (uPA) and its receptor (uPAR) strongly correlates with a malignant tumour cell phenotype. In the multistep process of metastasis, uPA binding to uPAR influences different cellular functions. In the present study, a highly metastatic colon cancer cell line, HCT116 was transfected with an expression vector containing a 5’ uPAR cDNA fragment in an antisense orientation. This construct was most effective in reducing uPAR cell surface expression as confirmed by flow cytometry analysis. Antisense transfection of HCT116 cells had no effect on proliferation but the following effects were observed: (1) a 1.3‐fold decreased adhesion; (2) a two‐fold decreased Erk MAP kinase activity; (3) a 2.7‐fold decrease in Src kinase activity; (4) a 1.5‐ and two‐fold decrease in uPA cell surface expression and secretion; (5) abrogation of promatrix metalloproteinase‐9 secretion; and (6) a complete suppression of plasminogen‐dependent matrix degradation. Using proteomic analysis, we demonstrate loss of approximately 200 proteins and quantitative differences in the expression of 141 other proteins in an antisense‐clone compared to wild‐type and mock‐transfected control. Such changes in protein expression with the down‐regulation of uPAR may be an important contributor in colon cancer progression and metastasis and may not only provide a basis to develop a proteomic data bank of uPAR‐mediated signaling molecules but may also lead to the development of therapeutic approaches for the cure and better management of colon cancer.
- 5 March 2003
- Published by Wiley in Proteomics
- Vol. 3 (3) , 288-298
Proteomic profiling of proteins associated with urokinase plasminogen activator receptor in a colon cancer cell line using an antisense approach
Expression of urokinase plasminogen activator (uPA) and its receptor (uPAR) strongly correlates with a malignant tumour cell phenotype. In the multistep process of metastasis, uPA binding to uPAR influences different cellular functions. In the present study, a highly metastatic colon cancer cell line, HCT116 was transfected with an expression vector containing a 5’ uPAR cDNA fragment in an antisense orientation. This construct was most effective in reducing uPAR cell surface expression as confirmed by flow cytometry analysis. Antisense transfection of HCT116 cells had no effect on proliferation but the following effects were observed: (1) a 1.3‐fold decreased adhesion; (2) a two‐fold decreased Erk MAP kinase activity; (3) a 2.7‐fold decrease in Src kinase activity; (4) a 1.5‐ and two‐fold decrease in uPA cell surface expression and secretion; (5) abrogation of promatrix metalloproteinase‐9 secretion; and (6) a complete suppression of plasminogen‐dependent matrix degradation. Using proteomic analysis, we demonstrate loss of approximately 200 proteins and quantitative differences in the expression of 141 other proteins in an antisense‐clone compared to wild‐type and mock‐transfected control. Such changes in protein expression with the down‐regulation of uPAR may be an important contributor in colon cancer progression and metastasis and may not only provide a basis to develop a proteomic data bank of uPAR‐mediated signaling molecules but may also lead to the development of therapeutic approaches for the cure and better management of colon cancer.
- 1 September 1998
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 13 (9) , 936-944
Expression of urokinase‐type plasminogen activator receptor and plasminogen activator inhibitor‐1 in gastric cancer
In gastric cancer, the urokinase‐type plasminogen activator (uPA) system plays important roles in invasion and metastasis, processes which entail proteolysis and adhesion. Both the urokinasetype plasminogen activator receptor (uPAR) and the plasminogen activator inhibitor‐1 (PAI‐1) are thought to be important factors in this system. To clarify the relationship between these two factors and gastric cancer invasiveness, we evaluated the expression of uPAR and PAI‐1 in 91 cases of gastric cancer by immunohistochemistry and in situ hybridization. Urokinase‐type plasminogen activator receptor‐mRNA, PAI‐1‐mRNA, uPAR and PAI‐1 protein were diffusely distributed in the cytoplasm of the cancer cells and concentrated at invasive foci. Urokinase‐type plasminogen activator receptor protein expression correlated with lymphatic, venous invasion (P<.01) and lymph node metastasis (PPPPP<0.05). This suggests that the proteolytic activity of uPAR and the cellular motility of PAI‐1 in gastric cancer cells may determine penetration of lymphatic and blood vessels, whereby lymph node metastasis may be promoted and that the promotion of cellular motility by PAI‐1 may influence the depth of cancer invasion.
- 1 September 1998
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 13 (9) , 936-944
Expression of urokinase‐type plasminogen activator receptor and plasminogen activator inhibitor‐1 in gastric cancer
In gastric cancer, the urokinase‐type plasminogen activator (uPA) system plays important roles in invasion and metastasis, processes which entail proteolysis and adhesion. Both the urokinasetype plasminogen activator receptor (uPAR) and the plasminogen activator inhibitor‐1 (PAI‐1) are thought to be important factors in this system. To clarify the relationship between these two factors and gastric cancer invasiveness, we evaluated the expression of uPAR and PAI‐1 in 91 cases of gastric cancer by immunohistochemistry and in situ hybridization. Urokinase‐type plasminogen activator receptor‐mRNA, PAI‐1‐mRNA, uPAR and PAI‐1 protein were diffusely distributed in the cytoplasm of the cancer cells and concentrated at invasive foci. Urokinase‐type plasminogen activator receptor protein expression correlated with lymphatic, venous invasion (P<.01) and lymph node metastasis (PPPPP<0.05). This suggests that the proteolytic activity of uPAR and the cellular motility of PAI‐1 in gastric cancer cells may determine penetration of lymphatic and blood vessels, whereby lymph node metastasis may be promoted and that the promotion of cellular motility by PAI‐1 may influence the depth of cancer invasion.